10-Q: Cue Biopharma Prioritizes Autoimmune Programs, Reports Q2 2024 Financial Results

Cue Biopharma shifts focus to autoimmune programs while reporting a net loss of $22.5 million for the first half of 2024, alongside ongoing clinical trial progress.

Summary

• Cue Biopharma is a clinical-stage biopharmaceutical company focused on developing T-cell modulating therapeutics.
• The company is shifting its strategic focus towards its autoimmune programs, CUE-401 and CUE-501, while continuing to pursue partnerships for its oncology programs.
• For the six months ended June 30, 2024, Cue Biopharma reported a net loss of $22.5 million, compared to a net loss of $26.3 million for the same period in 2023.
• Collaboration revenue increased to $4.4 million for the first half of 2024, up from $1.6 million in the first half of 2023, primarily due to the Ono collaboration.
• Research and development expenses were $19.7 million for the first half of 2024, a slight decrease from $20.0 million in the same period of 2023.
• General and administrative expenses decreased to $7.7 million for the first half of 2024, down from $8.4 million in the first half of 2023.
• As of June 30, 2024, the company had $30.0 million in cash and cash equivalents.
• The company believes its current cash will fund operations into the second quarter of 2025, but will need to raise additional capital to continue as a going concern.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive clinical results and strategic shifts, the company's financial situation and going concern warning temper the overall sentiment. The need for additional capital and the recent workforce reduction are concerning.

Positives

• The company's strategic shift towards autoimmune programs could lead to new opportunities and growth.
• The reduction in net loss compared to the previous year indicates improved financial management.
• The increase in collaboration revenue demonstrates the value of the company's partnerships.
• Clinical data for CUE-101 shows promising results in terms of overall survival and response rates.
• Preclinical data for CUE-401 and CUE-501 suggests potential for effective autoimmune treatments.

Negatives

• The company has a history of operating losses and negative cash flows.
• The company's recurring losses raise substantial doubt about its ability to continue as a going concern.
• The company is dependent on raising additional capital to fund its operations.
• The company has limited experience in conducting clinical trials and no history of commercializing biologic products.
• The company faces significant competition from other biotechnology and pharmaceutical companies.
• The company relies on third parties to conduct clinical trials and manufacture drug supplies.

Risks

• The company may not be able to achieve or maintain profitability.
• The company may not be successful in developing FDA-approved or commercialized products.
• The company is substantially dependent on the success of its drug product candidates.
• The company may not be able to establish collaborations or strategic alliances.
• The company's collaboration agreement with LG Chem contains exclusivity provisions that restrict research and development activities.
• The company may not be successful in identifying additional drug product candidates.
• The company faces significant competition from other biotechnology and pharmaceutical companies.
• The company relies on third parties to conduct clinical trials and manufacture drug supplies.
• The company may not be able to protect its intellectual property.
• The company will need substantial additional financing to support its growth and ongoing operations.
• The company's recurring losses from operations raise substantial doubt regarding its ability to continue as a going concern.
• The company has a loan agreement that requires it to meet certain operating covenants and place restrictions on its operating and financial flexibility.
• The company's stock price has recently closed below $1.00 per share, which could lead to delisting from Nasdaq.

Future Outlook

The company expects to continue the development of its autoimmune programs and pursue partnerships for its oncology programs. They anticipate providing further updates on the maturing monotherapy data in the fourth quarter of 2024 and combination data in the first half of 2025. The company believes its current cash will fund operations into the second quarter of 2025, but will need to raise additional capital to continue as a going concern.

Management Comments

• The company is shifting its strategic focus towards its autoimmune programs.
• The company is actively pursuing third party support through partnerships and collaborations to further develop the CUE-100 series programs.
• The company believes that the data generated to date underscores what appears to be a substantial extension of survival, evidenced by the median overall survival of multiple patient cohorts receiving CUE-101.
• The company anticipates selecting a clinical candidate and initiating IND-enabling studies for CUE-401 in the first half of 2025.
• The company anticipates providing a CUE-501 program update in the fourth quarter of 2024, with lead candidate selection anticipated to occur in the first quarter of 2025.

Industry Context

The shift towards autoimmune programs reflects a growing interest in this therapeutic area, while the company's ongoing oncology programs are aligned with the broader trend of developing targeted cancer therapies. The company's approach to T-cell modulation is consistent with the industry's focus on harnessing the immune system to fight disease.

Comparison to Industry Standards

• The reported median overall survival (mOS) of 20.8 and 24.6 months for CUE-101 monotherapy in 2L+ patients compares favorably to historical mOS data of 8.4 months with KEYTRUDA and 7.5 months with OPDIVO, both checkpoint inhibitors commonly used in this setting. This suggests a potential improvement in patient outcomes compared to standard treatments.
• The overall response rate (ORR) of 46% observed with CUE-101 in combination with KEYTRUDA is more than double the historical ORR of 19% observed with KEYTRUDA alone in the KEYNOTE 048 study. This indicates a potential synergistic effect of the combination therapy.
• The company's approach to redirecting memory T cells to deplete B cells with CUE-501 is similar to the mechanism of action of CD19-CAR-T cell therapy, but with the potential advantage of being an off-the-shelf biologic rather than a cell therapy. This could offer a more accessible and cost-effective treatment option.
• The company's focus on developing bispecific molecules like CUE-401, which combines IL-2 and TGF beta signals, is in line with the industry's trend of developing multi-functional biologics for complex diseases. This approach aims to enhance efficacy and specificity compared to single-target therapies.
• The company's financial results, with a net loss of $22.5 million for the first half of 2024, are typical for a clinical-stage biopharmaceutical company that is still in the development phase. The company's cash runway into the second quarter of 2025 is also consistent with the financial challenges faced by many companies in this sector.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Employees have been impacted by a 25% workforce reduction as part of the organizational restructuring.
• Customers (potential patients) may benefit from the development of new therapies for cancer and autoimmune diseases.
• Suppliers and creditors may be affected by the company's financial situation and need for additional funding.

Next Steps

• The company will continue to develop its autoimmune programs, CUE-401 and CUE-501.
• The company will pursue partnerships for its oncology programs, including CUE-101 and CUE-102.
• The company anticipates selecting a clinical candidate and initiating IND-enabling studies for CUE-401 in the first half of 2025.
• The company anticipates providing a CUE-501 program update in the fourth quarter of 2024, with lead candidate selection anticipated to occur in the first quarter of 2025.
• The company will continue to follow the patients treated in the CUE-102 Phase 1 monotherapy setting and anticipate providing further updates on the maturing data in the fourth quarter of 2024.
• The company will continue to follow the patients treated in both the CUE-101 Phase 1 monotherapy and combination settings and anticipate providing further updates on the maturing monotherapy data in the fourth quarter of 2024 and combination data in the first half of 2025.

Key Dates

Keywords

autoimmune, oncology, biopharmaceutical, clinical trials, T-cell modulation, Immuno-STAT, CUE-101, CUE-102, CUE-401, CUE-501, regulatory T cells, B cell depletion, collaboration, milestones, financial results